Browse studies, page 1081
Page 1081 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus Diabetes Therapy, 2013
- Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus Circulation, 2017
- Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial ( EASE ‐1) Diabetes Obesity and Metabolism, 2015
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Stroke, 2017
- The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes Journal of Clinical Medicine, 2019
- Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial Age and Ageing, 2019
- A P hase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes Diabetes Obesity and Metabolism, 2013
- Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus Diabetes and Vascular Disease Research, 2015
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial Journal of the American Society of Nephrology, 2018
- Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes European Heart Journal, 2020
- Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1β in type 2 diabetes patients Scientific Reports, 2022
- Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy, 2022
- Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study Expert Opinion on Drug Safety, 2022
- Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open‐label, crossover, active‐comparator FIORE trial Diabetes, obesity and metabolism, 2022
- Effect of empagliflozin on coronary microvascular function in patients with type 2 diabetes mellitus–A randomized, placebo-controlled cross-over study PLoS ONE, 2022
- Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China American Journal of Cardiovascular Drugs, 2022
- Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction Circulation. Cardiovascular Quality and Outcomes, 2022
- Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR‐Preserved trial European Journal of Heart Failure, 2022
- Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease JACC Cardiovascular Imaging, 2021
- Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients Frontiers in Pediatrics, 2022
- Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China Frontiers in Pharmacology, 2022
- Effect of empagliflozin versus linagliptin on body composition in Asian patients with type 2 diabetes treated with premixed insulin Scientific Reports, 2022
- The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial Clinical Research in Cardiology, 2022
- Effect of SGLT-2 inhibitor, empagliflozin, on blood pressure reduction in Chinese elderly hypertension patients with type 2 diabetes and its possible mechanisms Scientific Reports, 2022
- Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes – Data from a randomized, placebo-controlled study Bone Reports, 2022
- Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study Diabetes Care, 2022
- Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials Diabetes Care, 2022
- Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction JAMA Internal Medicine, 2022
- Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial American Heart Journal, 2022
- Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age Journal of the American College of Cardiology, 2022
- Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes Journal of Pharmacology and Experimental Therapeutics, 2022
- Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia : Experiences from the randomized, controlled SOCOGAMI trial Cardiovascular Diabetology, 2023
- Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40% ESC Heart Failure, 2023
- Dapagliflozin versus empagliflozin in patients with chronic kidney disease Frontiers in Pharmacology, 2023
- Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial European Review for Medical and Pharmacological Sciences, 2023
- Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure Journal of Clinical Medicine, 2023
- Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland ClinicoEconomics and Outcomes Research, 2023
- Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials European Journal of Heart Failure, 2023
- Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes International Journal of Molecular Sciences, 2023
- Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF Cardiovascular Research, 2024
- Effect of empagliflozin on weight in patients with prediabetes and diabetes Scientific Reports, 2025
- Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study Journal of cardiovascular medicine (Hagerstown, Md.), 2022
- Protecting cardiomyocytes from hypoxia-reoxygenation injury, empaglifozin and liraglutide alone or in combination? Journal of basic and clinical physiology and pharmacology, 2024
- Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics Cardiovascular diabetology, 2022
- Cubosomal functionalized block copolymer platform for dual delivery of linagliptin and empagliflozin: Recent advances in synergistic strategies for maximizing control of high-risk type II diabetes Drug delivery and translational research, 2024
- Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes Future cardiology, 2023
- Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes Diabetes, obesity & metabolism, 2021
- Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk Journal of diabetes and its complications, 2023
- Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction Pharmacotherapy, 2023
- SGLT-2 inhibitors reduce glucose absorption from peritoneal dialysis solution by suppressing the activity of SGLT-2 Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019
- Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors? Journal of cardiovascular pharmacology, 2024
- Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States Advances in therapy, 2021
- The effect of empagliflozin on P wave peak time and other P wave parameters in patients with diabetes mellitus Pacing and clinical electrophysiology : PACE, 2022
- The effect of empagliflozin on index of cardio-electrophysiological balance in patients with diabetes mellitus Pacing and clinical electrophysiology : PACE, 2023
- Effects of Semaglutide and Empagliflozin on Inflammatory Markers in Patients with Type 2 Diabetes International journal of molecular sciences, 2023
- Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis Clinical drug investigation, 2020
- Synthesis and Characterization of MIP Ghost Approach for Selective Extraction of Empagliflozin and Quantification by Liquid Chromatography Journal of chromatographic science, 2025
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Diabetes care, 2016
- Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality The American journal of cardiology, 2018
- A novel self-nanomicellizing system of empagliflozin for oral treatment of acute pancreatitis: An experimental study Nanomedicine : nanotechnology, biology, and medicine, 2022
- Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet . International journal of clinical pharmacology and therapeutics, 2017
- Empagliflozin, a sodium glucose cotransporter-2 inhibitor, ameliorates peritoneal fibrosis via suppressing TGF-β/Smad signaling International immunopharmacology, 2021
- Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress International journal of molecular sciences, 2021
- Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial American heart journal, 2020
- Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation Problemy endokrinologii, 2024
- Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats International journal of molecular sciences, 2022
- Real-World Eligibility and Cost-Effectiveness Analysis of Empagliflozin for Heart Failure in Korea Journal of Korean medical science, 2024
- Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus Naunyn-Schmiedeberg's archives of pharmacology, 2024
- Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy Cardiovascular diabetology, 2018
- EMPA-REG OUTCOME: The Cardiologist's Point of View The American journal of medicine, 2017
- The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy Journal of physiology and biochemistry, 2024
- Improvements of myocardial strain and work in diabetes patients with normal ejection fraction after empagliflozin treatment Journal of diabetes investigation, 2024
- Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trial Diabetes research and clinical practice, 2018
- Early SGLT2 inhibitor use is associated with improved left atrial strain following acute coronary syndrome Acta cardiologica, 2024
- Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin's impact on burden reduction Journal of medical economics, 2025
- The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition Diabetes, 2020
- Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease Diabetes research and clinical practice, 2022
- In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type Annals of internal medicine, 2024
- Pharmacokinetics, Safety, and Bioequivalence of Two Empagliflozin Formulations after Single Oral Administration under Fasting and Fed Conditions in Healthy Chinese Subjects: An Open-label Randomized Single-dose Two-sequence, Two-treatment, Two-period Crossover Study Pharmacotherapy, 2020
- Safety and effectiveness of empagliflozin and linagliptin fixed-dose combination therapy in Japanese patients with type 2 diabetes: final results of a one-year post-marketing surveillance study Expert opinion on drug safety, 2023
- Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study Medicina (Kaunas, Lithuania), 2022
- Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes Diabetologia, 2016
- Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study Expert opinion on drug safety, 2020
- An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells Cancer letters, 2020
- Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes Diabetes, obesity & metabolism, 2021
- Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial Journal of cardiac failure, 2021
- Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option International journal of clinical practice, 2015
- Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes PloS one, 2019
- Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice International journal of biological sciences, 2020
- Sex-, Species-, and Tissue-Specific Metabolism of Empagliflozin in Male Mouse Kidney Forms an Unstable Hemiacetal Metabolite (M466/2) That Degrades to 4-Hydroxycrotonaldehyde, a Reactive and Cytotoxic Species Chemical research in toxicology, 2015
- Empagliflozin in the treatment of type 2 diabetes: evidence to date Drug design, development and therapy, 2015
- Evaluating the efficacy and safety of empagliflozin addition to insulin and oral antidiabetic medication (OAD) regimen in poorly controlled type 2 diabetes and obese patients Pakistan journal of pharmaceutical sciences, 2024
- Empagliflozin's role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial Cardiovascular diabetology, 2024
- Comparative healthcare resource utilization and costs of empagliflozin and GLP-1 receptor agonists in type 2 diabetes Diabetes, obesity & metabolism, 2026
- Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction: A Post Hoc Analysis of the EMPEROR-Preserved Trial JAMA cardiology, 2023
- Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure European journal of heart failure, 2019
- Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial Diabetes, obesity & metabolism, 2020
- Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study Diabetes, obesity & metabolism, 2022
- Impact of empagliflozin add-on therapy on quality of life in patients of type 2 diabetes mellitus with hypertension: A prospective study Indian journal of public health, 2022
- Comparison of efficacy and safety of empagliflozin vs linagliptin added to premixed insulin in patients with uncontrolled type 2 diabetes: A randomized, open-label study Diabetes & metabolism, 2021
